Pretibial myxoedema: a case study of a 49-year-old male

Authors

  • Rajesh Rajagopalan Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India
  • Mohankumar Vedhanayagam Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India
  • Revathi Kandasamy Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India
  • Srinivasahan Karattupalayam Govindan Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India
  • Priyathileepan Thangavelu Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India
  • Sachin Subrahmanya K. Department of Dermatology, Venereology and Leprology, Government Erode Medical College, Perundurai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20250440

Keywords:

Grave’s disease, Thyrotoxicosis, Mucin deposition, Glycosaminoglycan’s

Abstract

Pretibial myxoedema (PTM), also known as thyroid dermopathy, is a rare but distinctive complication of Graves’ disease, often appearing as skin lesions on the shins. A 49-year-old male with thyrotoxicosis and diabetes presented with significant swelling in his lower legs, including the shins, ankles, and feet. Laboratory tests revealed normal thyroid function but elevated thyroid-stimulating hormone (TSH) receptor antibodies, confirming PTM diagnosis upon biopsy. Thyroid dermopathy is usually asymptomatic, but severe cases may result in elephantiasis or thyroid acropachy, often accompanying ophthalmopathy, which typically appears earlier. Diagnosis is made by identifying characteristic lesions in patients with a history of Graves' disease and ophthalmopathy, sometimes requiring biopsy for confirmation. Though many cases are mild and self-resolving, topical corticosteroids can provide relief in symptomatic or cosmetically concerning cases. In severe instances, systemic immunomodulation may be required, though evidence supporting its long-term efficacy is limited. The underlying pathogenesis involves immune-mediated fibroblast activation and glycosaminoglycan (GAG) production, particularly in the pretibial area due to mechanical factors. Studies show that subclinical dermopathy can occur in untreated Graves' disease, though histological changes in other areas like the forearm remain rare. Overall, treatment remains largely palliative, with more effective options still needed.

Metrics

Metrics Loading ...

References

Lan C, Wang Y, Zeng X, Zhao J, Zou X. Morphological diversity of pretibial myxedema and its mechanism of evolving process and outcome: a retrospective study of 216 Cases. J Thyroid Res. 2016;1:2652174. DOI: https://doi.org/10.1155/2016/2652174

Veeranna S, K, Betkerur J, S. Pretibial myxedema, ophthalmopathy and acropachy in a male patient with Graves disease. Indian J Dermatol Venereol Leprol 2004;70:380-382

Datta D, Bhushan M, Das A. Skin as an endocrine organ: A narrative review. Indian J Dermatol Venereol Leprol. 2022;88(5):590-7. DOI: https://doi.org/10.25259/IJDVL_533_2021

Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6(5):295-309. DOI: https://doi.org/10.2165/00128071-200506050-00003

Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol. 2003;48(5):641-59. DOI: https://doi.org/10.1067/mjd.2003.257

Christopher E, Griffiths M, Barker J, Bleiker TO, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. Ninth edition, John Wiley & Sons Inc., 2016: 4118-4119. DOI: https://doi.org/10.1002/9781118441213

Anderson CK, Miller OF 3rd. Triad of exophthalmos, pretibial myxedema, and acropachy in a patient with Graves' disease. J Am Acad Dermatol. 2003;48(6):970-2. DOI: https://doi.org/10.1067/mjd.2003.323

Kim WB, Mistry N, Alavi A, Sibbald C, Sibbald RG. Pretibial myxedema: case presentation and review of treatment options. Int J Low Ext Wounds. 2014;13(2):152-4. DOI: https://doi.org/10.1177/1534734614531485

Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Dermato-Venereolog. 1992;72(1):69-71. DOI: https://doi.org/10.2340/00015555726971

Kriss JP, Pleshakov V, Rosenblum A. Therapy with occlusive dressings of pretibial myxedema with fluocinolone acetonide. J Clin Endocrinol Metabol. 1967;27(5):595-604. DOI: https://doi.org/10.1210/jcem-27-5-595

Kuyvenhoven JP, van der Pijl JW, Goslings BM, Wiersinga WM. Graves’ dermopathy: does octreotide scintigraphy predict the response to octreotide treatment? Thyroid. 1996;6:385–9. DOI: https://doi.org/10.1089/thy.1996.6.385

Priestley GC, Aldridge RD, Sime PJ, Wilson D. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin) in vitro. Br J Dermatol. 1994;131:52–56. DOI: https://doi.org/10.1111/j.1365-2133.1994.tb08457.x

Downloads

Published

2025-02-24

How to Cite

Rajagopalan, R., Vedhanayagam, M., Kandasamy, R., Govindan, S. K., Thangavelu, P., & K., S. S. (2025). Pretibial myxoedema: a case study of a 49-year-old male. International Journal of Research in Dermatology, 11(2), 177–180. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20250440

Issue

Section

Case Reports